Retinal disease, vitreous and ocular oncology
Retinal reasoning distinguishes the neurosensory retina, retinal pigment epithelium, choroid, vessels and vitreoretinal interface. New flashes, floaters or a field curtain can reflect an acute vitreoretinal event and require assessment for a break or detachment. A posterior vitreous detachment is not identical to a retinal tear, but the events can coexist. Rhegmatogenous, tractional and exudative detachments arise through different mechanisms. Fluid configuration, traction, breaks, macular involvement and proliferative change influence the actual management question rather than one universal repair method.
Diabetic retinal disease is assessed through vascular lesions, ischemia, neovascularization and macular involvement. New vessels distinguish proliferative disease from nonproliferative categories, while edema and impaired central function have a related but separate assessment. Hard exudates suggest leakage but do not alone quantify retinal thickening. OCT, fundus examination and selected vascular imaging provide complementary information. Treatment selection depends on actual disease, visual function, follow-up capability and current evidence. A named historical trial should not be presented as proof that every later medicine was included in its comparison.
Retinal arterial occlusion is an urgent ocular and systemic problem. Acute symptomatic retinal arterial ischemia can require an immediate stroke-system assessment, including evaluation for important embolic and arteritic causes. A cherry-red appearance is a clue rather than a requirement for every case. Venous occlusions have different hemorrhagic and ischemic patterns and can later drive anterior or retinal neovascularization. Macular degeneration also requires distinguishing neovascular activity from nonexudative disease; fluid, hemorrhage and other imaging findings influence interpretation. A supplement or injection is not indicated solely because any druse or any visual complaint exists.
Ocular oncology includes pediatric and adult diseases with different diagnostic and genetic implications. Leukocoria can indicate retinoblastoma or another important condition and needs prompt assessment. RB1-related hereditary disease requires appropriate family and systemic considerations. Uveal and conjunctival melanocytic lesions need specialist interpretation of growth, imaging, tissue information and stage. Biopsy is not universally forbidden in uveal melanoma: selected diagnostic and prognostic sampling can be discussed by the appropriate specialist team. This differs from treating every suspected pediatric intraocular tumor as suitable for routine office sampling. Tumor appearance, histology, molecular information and the purpose of the investigation must be considered together.